Buruli ulcer (BU) is a cutaneous neglected tropical disease caused by Mycobacterium ulcerans. Synthesizing the evidence on their efficacy of antibiotic in the management of BU can help to better define their roles, identify weaknesses and inform clinicians on relevant measures than can be used to control BU. Our objectives is to assess the clinical efficacy of Rifampicin-Streptomycin given for 8 weeks of treatment of early M. ulcerans infection. We searched the following electronic databases from January 2005 to July 2012: Medline, EMBASE (Excerpta Medica Database), The Cochrane Library, Google Scholar, CINAHL (Cumulative Index to Nursing and Allied Health Literature), WHOLIS (World Health Organization Library Database), LILACS (Latin American and Caribbean Literature on Health Sciences) and contacted experts in the field. There were no restrictions to language or publication status. All study designs that could provide the information we sought for were eligible provided the studies were conducted in the third world. Critical appraisal of all identified citations was done independently by three authors to establish the possible relevance of the articles for inclusion in the review. Of the 115 studies, 09 papers met the inclusion criteria. The duration of treatment ranged from 8 to 48 weeks depending on the severity. Oral chemotherapy alone obtained a curative rate of 50%. The "dual" mode of treatment (surgery + chemotherapy) reduced hospital admission period from 90 to 39.8 days, that's to 44.2%. This treatment for early stages could therefore replace surgery and in severe cases, is an indispensable aid before surgery. These results confirmed that the daily administration of Rifampicin and Streptomycin is an effective treatment for M. ulcerans infection in an early stage. Subsequent systematic reviews should be conducted to determine if antibiotics could heal injuries without resorting to surgery and to compare different treatment durations.
Introduction

Buruli ulcer (BU) is a cutaneous Neglected Tropical Disease (NTD)
caused by Mycobacterium ulcerans [1] [2] [3] . It is the third most frequent mycobacterial infection after tuberculosis and leprosy [1, 2] .
A plasmid of M. ulcerans encodes the production of mycolactone ulcerans infection; to determine which oral antibiotics is more effective for managing BU with or without surgical excision.
Methods
Search strategy
We searched the following electronic databases from January 2005 Study design: All study designs were eligible for inclusion provided they were on antibiotic treatment.
Study participants:
Owing to the wide range of functions that fall under the umbrella term "clinical efficacy" we designed a definition of our own. For this review, we defined antibiotic treatment as individuals trained in the particular role of delivering curative or preventive care in the management of BU.
Types of interventions:
We included interventions if the description was adequate for us to establish that it was an antibiotic treatment of BU. Where such details were unclear, we contacted the study authors, whenever possible, for more information.
Outcomes: Any of the following outcomes were sought: 
Assessment of quality in included studies:
The included studies were not scored for quality.
Current status of knowledge
Our searches retrieved 115 studies, of which 09 are included in the review ( Figure 1 , Table 1 ).
Study characteristics
Nine studies including 3 Randomised Controlled Trials (RCTs) The average recovery period was 104 days (range, 30-212 days) [13] .
Clinical efficacy of Rifampin-Streptomycin: Oral chemotherapy alone obtained a curative rate of 50% [13] . One participant developed an injection abscess and two others developed an abscess near the lesion, which was incised and drained After haven completed the antibiotic therapy, patients should be followed for at least 10 months (a total of 12 months from the start of treatment) to confirm healing, evaluate eventual complications and notice any relapses [8].
All these results were obtained without toxic effect of antibiotics. 
Conclusion
These results confirmed that the daily administration of Rifampicin and Streptomycin is an effective treatment for M. ulcerans infection at an early stage. Subsequent systematic reviews should be conducted to determine whether antibiotics could heal injuries without resorting to surgery and to compare different treatment durations.
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